SARSCoV2

Vaccination breakthrough infections with SARS-CoV-2 variants

COVAXIN effective against several variants of SARS-COV-2, double mutant strain: ICMR

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

In the development of mink infects the risk of SARS-CoV-2 for humans

10 Reasons Air Transmission of SARS-CoV-2 appears Airy

SARS-CoV-2 variant found in Brazil: Contagious, may limit immunity

SARS-CoV-2 antibody response in persons with natural infection in the past

Multilevel proteomics reveals host disturbances by SARS-CoV-2 and SARS-CoV

Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351

Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y.V2 (B.1.351)

The susceptibility of circulating SARS-CoV-2 variants to neutralization

Individual SARS-CoV-2 neutralizing antibody immunity lasts from days to decades